101 results
425
EX-2.2
OCGN
Ocugen Inc
8 Apr 19
Business combination disclosure
7:15am
company law, or if Stockholder is a married individual and resides in a state with community property laws, the community property interest of his or her … spouse to the extent applicable under such community property laws, which spouse hereby consents to this Agreement by executing the spousal consent
8-K
EX-2.2
OCGN
Ocugen Inc
8 Apr 19
Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage
7:17am
company law, or if Stockholder is a married individual and resides in a state with community property laws, the community property interest of his or her … spouse to the extent applicable under such community property laws, which spouse hereby consents to this Agreement by executing the spousal consent
8-K
EX-2.3
OCGN
Ocugen Inc
8 Apr 19
Histogenics and Ocugen Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage
7:17am
in a state with community property laws, the community property interest of his or her spouse to the extent applicable under such community property laws … hereto unless the Stockholder can demonstrate to Parent’s and Company’s reasonable satisfaction that his or her spouse does not have any community
425
EX-2.3
OCGN
Ocugen Inc
8 Apr 19
Business combination disclosure
7:15am
in a state with community property laws, the community property interest of his or her spouse to the extent applicable under such community property laws … hereto unless the Stockholder can demonstrate to Parent’s and Company’s reasonable satisfaction that his or her spouse does not have any community
8-K
EX-99.1
OCGN
Ocugen Inc
22 Dec 23
Other Events
3:09pm
genetic mutation. Advancing OCU400 to Phase 3 clinical development will be an important step toward addressing unmet needs in the RP patient community
S-1
EX-10.31
g06 t5yscvppz
7 Oct 14
IPO registration
12:00am
8-K
EX-99.3
l9uhsp0e9e4bn 8yqud3
1 Nov 22
Regulation FD Disclosure
8:15am
8-K
EX-99.2
e4y7t0x
6 Aug 21
Ocugen Provides Business Update and Second Quarter 2021 Financial Results
7:40am
8-K
EX-99.2
yjkewzghc tvppasslb
6 May 22
Ocugen Provides Business Update and First Quarter 2022 Financial Results
6:44am
8-K
EX-99.2
urzleb4uson7jul
25 Feb 22
Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results
7:41am
8-K
EX-99.1
w966g1xauqif cns1cv
9 Dec 21
Other Events
9:01am
8-K
EX-99.2
96ctcsxbgvi7
9 Nov 21
Ocugen Provides Business Update and Third Quarter 2021 Financial Results
7:35am
8-K
EX-99.1
9i0v97n tn
22 Feb 22
Other Events
7:36am
8-K
EX-99.1
eoum2bykr43a2k7sig7
8 Nov 21
Ocugen, Inc. Announces Submission of Investigational New Drug Application
9:25am
8-K
EX-99.1
dpo3ft r0
15 Jul 21
Other Events
4:08pm
8-K
EX-99.1
39a dxut06a67jt
23 May 22
Other Events
9:02am
8-K
EX-99.1
pdn0l fc4eb93
26 Nov 21
Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating
7:38am
8-K
EX-99.1
82niz7htgq j5airz
10 Jun 21
Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate
2:17pm
8-K
EX-99.1
5a2m b3km
22 Apr 21
Other Events
6:01am
8-K
EX-99.1
1n6l0eqpil2ogd0dyk1u
27 Oct 21
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
8:10am